BMKDF Stock — BioMark Diagnostics Inc

BioMark Diagnostics Inc (BMKDF)

Updated October 9, 2026.

BMKDF is a Stock. Total return is 9.2% over the past 11.5 years, 338.8 points behind SPY at 348.0%.

BioMark Diagnostics develops early-stage cancer diagnostic technology, focusing on liquid biopsy metabolic panel assays for detecting lung cancer, glioblastoma, breast cancer, and other cancer types. The company does not currently have an established distribution schedule. This security may appeal to investors seeking exposure to early-stage oncology diagnostics and biotech innovation, though it carries the risks associated with development-stage healthcare companies.

BMKDF performance versus SPY

Price and return data through 2026-10-09.

Total return is 9.2% over the past 11.5 years, 338.8 points behind SPY at 348.0%. Over the past year its total return — price change plus distributions reinvested — is 59.0%. Its deepest 1-year drawdown was 32.1%.

BMKDF key facts

Asset type

Stock

Asset class

Equity

Inception date

03/23/2015

Distribution frequency

None

Last close

$0.38 (stale; as of 2026-10-09)

Market cap

$40,133,607

Average volume

0.0

Beta

-0.375

Payout ratio

0.0%

EPS

$-0.02

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BMKDF risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 32.1%.

Who may consider BMKDF — and who may not

It is a weaker fit for investors who need monthly cash flow (BMKDF does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on BMKDF

• All tickers starting with B

Tagged: Healthcare.

Frequently asked questions